Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that extensive generic erosion, particularly in the first-line topical corticosteroids and adjunctive therapy antihistamine drug classes, coupled with a lack of innovative emerging therapies, will constrain the atopic dermatitis drug market over the next decade in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The new Pharmacor report entitled Atopic Dermatitis finds that generic erosion of antihistamines will cause drug sales in this class to plunge by 61 percent from 2007 to 2017. Antihistamines, along with topical calcineurin inhibitors and topical corticosteroids, dominate the atopic dermatitis drug market, accounting for 96 percent of major market sales in 2007. Topical calcineurin inhibitors -- Novartis's Elidel and Astellas's Protopic -- and topical corticosteroids are the primary treatment options used to treat the chronic skin disorder.

The report finds that the generic erosion of all major drug classes in atopic dermatitis and the dearth of effective emerging agents will cause the market to decline from $706.5 million in 2007 to just over $552 million in 2017.

"While most interviewed physicians indicate they are satisfied with the availability and cost of topical therapy for acute treatment, they continue to seek an effective systemic agent for maintenance therapy of this chronic disorder," said Greg Dwyer, analyst at Decision Resources. "There are currently no drugs in development that address this unmet need."

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Decision Resources                   Decision Resources, Inc.   Christopher Comfort                  Elizabeth Marshall   781-296-2597                         781-296-2563   ccomfort@dresources.com              emarshall@dresources.com 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources

CONTACT: Christopher Comfort of Decision Resources, +1-781-296-2597,
ccomfort@dresources.com; or Elizabeth Marshall of Decision Resources, Inc.,
+1-781-296-2563, emarshall@dresources.com

Sales of Anticoagulants for the Treatment of St-Elevation Myocardial Infarction Will Double Over the Next 10 Years

View Now